These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 9615133)

  • 1. [Hypertriglyceridemia induced by interferon].
    Iborra C; Martinet C; Prigent F
    Ann Dermatol Venereol; 1996; 123(10):677. PubMed ID: 9615133
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of hypertriglyceridemia in patients receiving interferon for malignant melanoma.
    Wong SF; Jakowatz JG; Taheri R
    Ann Pharmacother; 2004 Oct; 38(10):1655-9. PubMed ID: 15304625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertriglyceridaemia following adjuvant interferon-alpha treatment in two patients with malignant melanoma.
    Junghans V; Rünger TM
    Br J Dermatol; 1999 Jan; 140(1):183-4. PubMed ID: 10215802
    [No Abstract]   [Full Text] [Related]  

  • 4. [Hypertriglyceridemia following treatment with interferon alpha in essential thrombocythemia].
    De Salvo L; Plumacher Z; Gómez O; Weir-Medina J; Paz L; Salas D
    Invest Clin; 1996 Sep; 37(3):177-81. PubMed ID: 8983355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to manage melanoma in a psoriatic patient.
    Papadavid E; Psyrri A; Pectasides D; Katoulis A; Balamoti E; Dalamaga M; Stavrianeas N
    Dermatology; 2008; 216(3):277-8. PubMed ID: 18196939
    [No Abstract]   [Full Text] [Related]  

  • 6. [Sarcoidosis, myasthenia gravis and anterior ischaemic optic neuropathy: severe side effects of adjuvant interferon-alpha-therapy in malignant melanoma?].
    Kreutzer K; Bonnekoh B; Franke I; Ulrich J; Gollnick H
    J Dtsch Dermatol Ges; 2004 Aug; 2(8):689-94. PubMed ID: 16279234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
    Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
    J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertrichosis in three patients treated with interferon-alpha2.
    Kiecker F; Hofmann MA; Trefzer U
    Clin Exp Dermatol; 2009 Oct; 34(7):e414-5. PubMed ID: 19663862
    [No Abstract]   [Full Text] [Related]  

  • 9. Adjuvant interferon therapy and rheumatoid arthritis--a contraindication?
    Tsianakas A; Schiller M; Luger TA; Sunderkoetter C
    Acta Oncol; 2009; 48(3):468-9. PubMed ID: 18759142
    [No Abstract]   [Full Text] [Related]  

  • 10. Interferon alfa in the postsurgical management of high-risk melanoma: is it worth it?
    Glaspy J; Ribas A; Chmielowski B
    J Clin Oncol; 2009 Jun; 27(18):2896-7. PubMed ID: 19433677
    [No Abstract]   [Full Text] [Related]  

  • 11. [Severe hypertriglyceridemia during the course of treatment with interferon-alpha in a patient with chronic hepatitis C].
    Bory E; García Rico A; Pedro-Botet J; Sola R
    Gastroenterol Hepatol; 1996 Dec; 19(10):542. PubMed ID: 9044758
    [No Abstract]   [Full Text] [Related]  

  • 12. [Seizures during interferon alpha therapy: three cases in dermatology].
    Legroux-Crespel E; Lafaye S; Mahé E; Picard-Dahan C; Crickx B; Sassolas B; Descamps V
    Ann Dermatol Venereol; 2003 Feb; 130(2 Pt 1):202-4. PubMed ID: 12671585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
    Ridolfi L; Fiorentini G; Guida M; Michiara M; Freschi A; Aitini E; Ballardini M; Bichisao E; Ridolfi R;
    Melanoma Res; 2009 Apr; 19(2):100-5. PubMed ID: 19262411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant interferon therapy for melanoma.
    Hancock B; Wheatley K; Ives N; Gore M
    J Clin Oncol; 2005 Apr; 23(10):2431; author reply 2431-2. PubMed ID: 15800339
    [No Abstract]   [Full Text] [Related]  

  • 15. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?
    Schuchter LM
    J Clin Oncol; 2004 Jan; 22(1):7-10. PubMed ID: 14665612
    [No Abstract]   [Full Text] [Related]  

  • 16. Malignant melanoma (non-metastatic).
    Crosby T; Mason M; Savage P
    Clin Evid; 2003 Dec; (10):1897-909. PubMed ID: 15555184
    [No Abstract]   [Full Text] [Related]  

  • 17. Malignant melanoma (non-metastatic).
    Crosby T; Mason M; Savage P
    Clin Evid; 2004 Dec; (12):2321-35. PubMed ID: 15865791
    [No Abstract]   [Full Text] [Related]  

  • 18. Human recombinant interferon alpha-2a (r IFN alpha-2a) therapy suppresses hepatic triglyceride lipase, leading to severe hypertriglyceridemia in a diabetic patient.
    Yamagishi S; Abe T; Sawada T
    Am J Gastroenterol; 1994 Dec; 89(12):2280. PubMed ID: 7977268
    [No Abstract]   [Full Text] [Related]  

  • 19. Malignant melanoma (non-metastatic).
    Crosby T; Mason M; Savage P
    Clin Evid; 2005 Dec; (14):2058-72. PubMed ID: 16620482
    [No Abstract]   [Full Text] [Related]  

  • 20. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b.
    Moschos SJ; Kirkwood JM; Konstantinopoulos PA
    J Clin Oncol; 2004 Jan; 22(1):11-4. PubMed ID: 14665613
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.